Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6348868 | 0.95 | HSP90AA1 (0.52) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL5491197 | 0.92 | MEN1 (0.49) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL18340274 | 0.90 | HSP90AA1 (0.49) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL18339371 | 0.90 | HSP90AA1 (0.49) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL6616312 | 0.90 | HSP90AA1 (0.49) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL5486510 | 0.88 | KMT2A (0.46) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL6338942 | 0.85 | MEN1 (0.47) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL6338945 | 0.85 | MEN1 (0.47) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL6339170 | 0.85 | MEN1 (0.47) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL6478814 | 0.81 | HSP90AA1 (0.47) | MEN1KMT2AALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021065893-A1 | TETRALIN DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | 国立大学法人 筑波大学 | 2021-04-08 | — | — | WO | disclosed |
| CN-107501099-B | Modulators of ATP-binding cassette transporters | 沃泰克斯药物股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3216787-B1 | INTERMEDIATES FOR THE PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
| US-20180194731-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-07-12 | — | — | US | disclosed |
| WO-2000068230-A1 | 9-(1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)-1,9-DIHYDROPURIN-6-ONE DERIVATIVES AS PDE7 INHIBITORS | DARWIN DISCOVERY LIMITED (GB) | 2000-11-16 | — | — | WO | disclosed |
| US-6093727-A | A SELECTIVE AGONISTS FOR HUMAN ALPHA 2 RECEPTORS FOR TREATING DISORDERS AS HYPERTENSION, PAIN, GLAUCOMA, ALCOHOL AND DRUG WITHDRAWAL, ISCHEMIA, RHEUMATOID ARTHRITIS, MIGRAINE, COGNITIVE DEFICIENCY, SPASTICITY, DIARRHEA, NASAL CONGESTION | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-07-25 | — | — | US | disclosed |
| US-5981541-A | ACRIDINE DERIVATIVES; ANTICANCER AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0950054-A1 | SUBSTITUTED HETEROCYCLES AS ANTI-TUMOR AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-10-20 | — | — | EP | disclosed |
| US-5866579-A | SELECTIVE AGONISTS FOR CLONED HUMAN ALPHA-2 ADRENERGIC RECEPTORS. | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998012181-A1 | SUBSTITUTED HETEROCYCLES AS ANTI-TUMOR AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1998-03-26 | — | — | WO | disclosed |
| EP-0329563-B1 | BENZOCYCLOHEXANE AND BENZOCYCLOHEPTANE DERIVATIVES AND THEIR SALTS, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION, THEIR USE AS MEDICINES AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1993-04-21 | — | — | EP | disclosed |
| US-5130329-A | Amino, amide substituted compounds | ROUSSEL UCLAF (FR) | 1992-07-14 | — | — | US | disclosed |
| US-5068244-A | Benzcarbocyclic amides with nitro groups | ROUSSEL UCLAF (FR) | 1991-11-26 | — | — | US | disclosed |
| EP-0329563-A2 | Benzocyclohexane and benzocycloheptane derivatives and their salts, process and intermediates for their preparation, their use as medicines and compositions containing them | ROUSSEL-UCLAF (FR) | 1989-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | MEN1 4698/4885KMT2A 4245/4885ALDH1A1 2165/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | MEN1 4698/4885KMT2A 4245/4885ALDH1A1 2165/4885 |
| US-20180194731-A1 | THERAPEUTIC COMPOUNDS | SIRT2, SIRT1, SIRT3 | MEN1 2112/4885KMT2A 195/4885ALDH1A1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.